We recently showed that GARP-expressing Tregs were required for the anti-tumor activity of antibodies that block production of active TGF-β1 from GARP:TGF-β1 complexes on the surface of Tregs in mice transplanted with syngeneic colon carcinoma cells [67]. This evidence concerns the gene LRRC32 and colon carcinoma.